This article was downloaded by: On: 22 January 2011 Access details: Access Details: Free Access Publisher Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713454007

Two eudesmane sesquiterpenes from Laggera pterodonta

Y. -B. Liu^a; W. Jia^b; W. -Y. Gao^a; A. -H. Zhao^b; Y. -W. Zhang^c; Y. Takaishi^d; H. -Q. Duan^c ^a College of Pharmaceutical Science and Biotechnology, Tianjin University, Tianjin, China ^b School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China ^c School of Pharmacy, Tianjin Medical University, Tianjin, China ^d Faculty of Pharmaceutical Sciences, University of Tokushima, Tokushima, Japan

To cite this Article Liu, Y. -B., Jia, W., Gao, W. -Y., Zhao, A. -H., Zhang, Y. -W., Takaishi, Y. and Duan, H. -Q.(2006) 'Two eudesmane sesquiterpenes from *Laggera pterodonta*', Journal of Asian Natural Products Research, 8: 4, 303 – 307 **To link to this Article: DOI:** 10.1080/10286020500034964 **URL:** http://dx.doi.org/10.1080/10286020500034964

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.



Two eudesmane sesquiterpenes from Laggera pterodonta

Y.-B. LIU[†], W. JIA[‡], W.-Y. GAO[†], A.-H. ZHAO[‡], Y.-W. ZHANG[¶], Y. TAKAISHI§ and H.-Q. DUAN[¶]*

College of Pharmaceutical Science and Biotechnology, Tianjin University, Tianjin 300072, China
\$School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200030, China
\$School of Pharmacy, Tianjin Medical University, Tianjin 300070, China

§Faculty of Pharmaceutical Sciences, University of Tokushima, Shomachi 1-78, Tokushima 770-8505, Japan

(Received 16 August 2004; revised 29 September 2004; in final form 15 October 2004)

The phytochemical study of the aerial parts of *Laggera pterodonta* afforded two new eudesmane sesquiterpenes, 3α , 4β , 11-trihydroxyenantioeudesmane (pterodontriol E) (1) and 4β , 8β , 11-trihydroxyenantioeudesmane (pterodontriol F) (2), along with seven known compounds. Their structures were elucidated on the basis of spectroscopic data.

Keywords: Laggera pterodonta; Eudesmane sesquiterpenes; Pterodontriols; Pterodontriol E; Pterodontriol F

1. Introduction

Laggera pterodonta (DC.) Benth is widely distributed in southwestern China, mainly in Yunnan province. The aerial part of *L. pterodonta* has been used as folk medicine dating from ancient times. Pharmacological research indicated that extract of *L. pterodonta* has antileukaemia, anti-bacterial, anti-inflammatory and anti-malarial activities [1-3]. Many eudesmane sesquiterpenes and related glucosides, as well as flavonoids, have been reported from *L. pterodonta* [3–13]. In our search for pharmacologically active compounds from crude drugs of plant origin, the chemical constituents of *L. pterodonta* were studied. This paper deals with the isolation and structural elucidation of two new and seven known compounds (1–9) from the aerial parts of *L. pterodonta*.

2. Results and discussion

The ethyl acetate-soluble fraction from *Lagger pterodonta* was separated by repeated silicagel column chromatography, HPLC and gel permeation chromatography (GPC), to give two

^{*}Corresponding author. E-mail: duanhq@tijmu.edu.cn

Y.-B. Liu et al.

new sesquiterpenes, named pterodontriol E (1) and pterodontriol F (2), as well as seven known compounds (3-9).

Pterodontriol E (1) was obtained as an amorphous powder, exhibiting a molecular ion peak at m/z 279.1939 [M + Na]⁺ (HR FTMS), indicating a molecular formula of C₁₅H₂₈O₃ for 1. The IR spectrum showed the presence of hydroxyl group (3321 cm⁻¹). The ¹H NMR spectral data of 1 revealed the presence of four methyl groups [δ_H 1.29, 1.28, 1.05, and 0.91 (each 3H, s)] and one oxygenated methine proton signal [$\delta_{\rm H}$ 3.45 (1H, dd, J = 4.5, 11.9 Hz)]. Its ¹³C NMR spectral data showed 15 carbons, including four methyls, five methylenes, one oxygenated methine, two oxygenated quaternary carbons and other three carbon signals. Based on the above facts, compound 1 was proposed to be a eudesmane sesquiterpene, the same as pterodontriols A–D isolated from the same plant [3–5]. The ¹³C NMR spectral data of 1 were similar to those of pterodondiol [5], except for C-2 and C-3. In the HMBC spectrum of 1, the proton signal at $\delta_{\rm H}$ 0.91 (H-14) was correlated with the carbon signals at $\delta_{\rm C}$ 47.2 (C-5), 41.3 (C-9), 39.7 (C-1) and 34.3 (C-10), the signal at $\delta_{\rm H}$ 1.05 (H-15) was correlated with the signals at $\delta_{\rm C}$ 79.9 (C-3), 76.5 (C-4), and 47.2 (C-5), while the signal at $\delta_{\rm H}$ 3.45 (H-3) was correlated with the signals at $\delta_{\rm C}$ 76.5 (C-4), 27.5 (C-2), and 15.7 (C-15). Therefore, the hydroxyl group was located at the C-3 position. Thus, compound 1 should be a 3-hydroxy pterodondiol.

In the NOESY spectrum, the proton signal at $\delta_{\rm H}$ 3.45 (H-3) was correlated with the signals at $\delta_{\rm H}$ 1.68 (H-5) and 1.42 (H-1 β); the methyl signal at $\delta_{\rm H}$ 0.91 (H-14) was correlated with the signal at $\delta_{\rm H}$ 1.05 (H-15). Furthermore, the coupling constant of H-3 (J = 4.5, 11.9 Hz) indicated that it has axial orientation. Thus, the relative configurations of two hydroxyl groups were determined as 3α and 4β . According to the literature [3–5,11,12], all the pterodontriols isolated from *L. pterodonta* (including known compounds **3**–**7**, see section 3) have positive [α]_D values and their structures were determined as enantio-eudesmantriol by comparing with [α]_D values to those of eudesmantriols. Therefore, the positive [α]_D value (+78.6) of 1 indicated pterodontriol E (**1**) was apparently also an enantio-eudesmantriol. The structure of pterodontriol E was thus determined as shown in figure 1.

Pterodontriol F (2) had the molecular formula $C_{15}H_{28}O_3$, the same as 1. The ¹H NMR spectral data of 2 showed the presence of four methyl groups [δ_H 1.65, 1.58, 1.35, and 0.99 (each3H, s)], and one oxygenated methine proton signal [δ_H 4.66 (1H, ddd, J = 8.1, 8.1, 5.3 Hz)]. Comparing the ¹³C NMR spectral data of 2 with those of 1, compound 2 also appeared to be a eudesmane sesquiterpene with three hydroxyl groups (table 1). In the HMBC spectrum of 2, the methyl proton signal at δ_H 0.99 (H-14) was correlated with the carbon signals at δ_C 49.0 (C-5), 43.4 (C-1), and 52.6 (C-9), the signal at δ_H 1.81 (H-9a) was correlated with the signals at δ_C 21.2 (C-14), 69.8 (C-8), 47.1 (C-7), while the signal at δ_H 2.66 (H-6a) was correlated with the signals at δ_C 35.4 (C-10) and 69.8 (C-8). In turn, the methine signal at δ_H 4.66 (H-8) was correlated with the signal at δ_C 74.9 (C-11). Thus, the secondary hydroxyl group was located at the C-8 position. In the NOESY spectrum, the methyl proton signal at δ_H 0.99 (H₃-14) was correlated with the signals at δ_C 11.5 (H-15) and 4.66 (H-8). Thus, the two hydroxyl groups have 4 β and 8 β orientations. Therefore, pterodontriol F (2) was determined as 4 $\beta_8\beta_8\beta_11$ -trihydroxyenantioeudesmane (figure 1).

Several known compounds were identified by their spectroscopic data in comparison with literature values as follows: pterodontriol A (3) [5], pterodontriol B (4) [5], pterodontriol C (5) [3], laggerone A (6) [3], pterodondiol (7) [5], pendultin (8) [13], chrysosptertin (9) [13].

304

Two eudesmane sesquiterpenes



3. Experimental

3.1 General experimental procedures

NMR analysis of samples were performed with a Bruker AVANCE 300 instrument (¹H 300 MHz, ¹³C 75 MHz), both with teramethylsilane as an internal standard. HR FTMS data and EIMS data were obtained on Bruker Apex 7.0 Tesla and VG ZAB-HS (70 eV) instruments, respectively. Column chromatography was performed on silica-gel (Qingdao Haiyang Chemical Co. Ltd), Sephadex LH-20 (Amersham Pharmacia Biotech) and Toyopearl HW-40 (TOSOH). HPLC was a JASCO Gulliver Series with PU-1580 (pump), RI-1530 and UV-1575 (detector). Preparative HPLC column was used as follows: ODS (YMC-Pack ODS-A, SH-343-5), GPC (Shodex, Asahipak GS-310, 20 G, MeOH), Si-HPLC (Hibar RT 250-25, Lichrosorb, Si60 7 μ m). IR spectra were recorded on a FTS3000 Infrared Fourier Transform sepectrometer (Bio-Rad). Optical rotation was measured with a MC 241 digital polarimeter (Perkin-Elmer).

3.2 Plant material

Laggera pterodonta (DC.) Benth was purchased from Kunming, Yunnan province of China in August 2002 and identified by Professor Wen-Yuan Gao. A voucher specimen (D20020818) is deposited at the College of Pharmaceutical Science and Biotechnology, Tianjin University, China.

3.3 Extraction and isolation

The dried aerial parts (0.85 kg) of *L. pterodonta* were crushed and extracted three times with EtOH (95%, 10 L each) at 60°C for 6 h. The EtOH extract was concentrated under reduced

Y.-B. Liu et al.

pressure to give a residue (110 g), which was suspended in H₂O, and then partitioned with petroleum ether, EtOAc and n-BuOH, respectively. The EtOAc layer was concentrated to afford a residue (12 g), which was subjected to column chromatography with silica gel, and was eluted with solvents of increasing polarity [CHCl₃/MeOH (95:5, 9:1, 8:2, MeOH)] to yield eight fractions. Fraction 7 (439 mg) was chromatographed on Sephadex LH-20 (MeOH) to give four fractions (fr. 7.1-7.4). Fraction 7.2 (298 mg) was purified by HPLC (ODS, MeOH/H₂O 8:2, and then 7:3) to give 1 (13.8 mg) and 4 (11 mg). Fraction 5 (643 mg) was chromatographed on Toyopearl HW-40 (CHCl₃/MeOH, 2:1) to give three fractions (fr. 5.1-5.3). Fraction 5.2 (349 mg) was chromatographed on ODS column (MeOH/H₂O 8:2) to give seven fractions (fr. 5.2.1–5.2.7). Fraction 5.2.4 (22 mg) was purified by HPLC (GPC, MeOH) to give 2 (8.5 mg). Fraction 5.2.3 (35 mg) was separated by Si-HPLC (CHCl₃/MeOH, 95:5) to give 5 (4.5 mg) and 6 (4 mg). Fraction 4 (1.5 g) was chromatographed on Sephadex LH-20 (MeOH) to give four fractions (fr.4.1-4.4). Fraction 4.3 was further chromatographed on a silica-gel column [CHCl₃/MeOH (95:5, 9:1)] to give three fractions (fr. 4.3.1–4.3.3). Fraction 4.3.2 (346 mg) was separated by HPLC (ODS, MeOH/H₂O 8:2) to give 7 (55 mg). Fraction 8 (513 mg) was chromatographed on LH-20 (MeOH) to give four fractions (fr. 8.1–8.4). Fraction 8.3 (110 mg) was separated by HPLC (ODS, MeOH/H₂O 8:2, and then Si-60, CHCl₃/MeOH, 85:15) to give **3** (18.6 mg). Fraction 3 (1.2 g) was chromatographed on silica-gel column [CHCl₃/MeOH (99:1, 98:2, 95:5, 9:1)] to give five fractions (fr. 3.1-3.5). Fraction 3.4 (463 mg) was chromatographed on Toyopearl HW-40 (CHCl₃—MeOH, 2:1) to give four fractions (fr. 3.4.1–3.4.4). Fraction 3.4.3 (110 mg) was separated by Si-HPLC (CHCl₃/MeOH, 97:3) to give 8 (6.7 mg) and 9 (13.6 mg).

Pterodontriol E (1) was isolated as an amorphous powder, $[\alpha]_D^{25} + 78.6 (c \ 1.5, CHCl_3)$. IR (KBr) $\nu_{\text{max}} \text{ cm}^{-1}$: 3321, 2945, 1459, 1406, 1387, 1265, 1220, 1186, 1150, 1089, 1067, 1035, 984, 907, 859. EI-MS: $m/z \ 256 \ [M]^+(1)$, 238 (10), 220 (8), 205 (9), 179 (31), 147 (21), 123 (31), 95 (30), 59 (55), 43 (100), 27 (9). HR-FTMS $m/z \ 279.1939 \ [M + Na]^+$ (calcd for $C_{15}H_{28}O_3Na \ 279.1931$). ¹H NMR and ¹³C NMR (CDCl₃) data are listed in table 1.

Pterodontriol F (**2**) was isolated as an amorphous powder, $[\alpha]_D^{25} + 45.2$ (*c* 0.8, CHCl₃). IR (KBr) ν_{max} cm⁻¹: 3369, 2930, 1459, 1384, 1173, 1101, 1050, 942, 914, 756. EI-MS: *m/z*

| Table 1. H NMR and C NMR spectral data of I and | Table 1. | H NMR ar | d ¹³ C NMR | spectral | data of | 1 and |
|---|----------|----------|-----------------------|----------|---------|-------|
|---|----------|----------|-----------------------|----------|---------|-------|

| No. | ¹³ C | 1 (CDCl ₃) | | $2(C_5D_5N)$ | | |
|-----|-----------------|----------------------------|-----------------|--------------------------------|--|--|
| | | $^{-1}H^{a}$ | ¹³ C | $^{1}H^{a}$ | | |
| 1 | 39.7 | 1.42,1.22 (m) | 43.4 | 1.48,1.27 (m) | | |
| 2 | 27.5 | 1.71,1.51 (m) | 21.4 | 1.69,1.53 (m) | | |
| 3 | 79.9 | 3.45 (dd, 4.5, 11.9) | 44.8 | 1.97,1.71 (m) | | |
| 4 | 76.5 | _ | 71.7 | _ | | |
| 5 | 47.2 | 1.68 (m) | 49 | 2.27 (m) | | |
| 6 | 20.4 | 2.09 (brd, 13.6), 1.49 (m) | 21.5 | 2.68 (dt, 14.2, 4.4), 1.70 (m) | | |
| 7 | 41.3 | 1.67 (m) | 47.1 | 2.30 (m) | | |
| 8 | 21.3 | 1.75,1.65 (m) | 69.8 | 4.66 (ddd, 8.1, 8.1, 5.3) | | |
| 9 | 41.3 | 1.47,1.19 (m) | 52.6 | 2.05, 1.81 (m) | | |
| 10 | 34.3 | _ | 35.4 | _ | | |
| 11 | 74.9 | _ | 74.9 | _ | | |
| 12 | 29.6 | 1.29 (s) | 30.2 | 1.58 (s) | | |
| 13 | 30 | 1.28 (s) | 31.9 | 1.65 (s) | | |
| 14 | 18.8 | 0.91 (s) | 21.2 | 0.99 (s) | | |
| 15 | 15.7 | 1.05 (s) | 23.3 | 1.35 (s) | | |

^a The chemical shift of proton signals was read by HSQC spectrum.

256 $[M]^+(1)$, 238 (2), 220 (10), 205 (12), 177 (53), 162 (49), 109 (29), 95 (45), 59 (54), 43 (100), 27 (11). HR-FTMS *m/z* 279.1944 $[M + Na]^+$ (calcd for C₁₅H₂₈O₃Na 279.1931). ¹H NMR and ¹³C NMR (C₅D₅N) data are listed in table 1.

 $[\alpha]_{D}$ values of **3**–**7**: **3**, $[\alpha]_{D}^{25}$ 22.7 (*c* 0.22, MeOH); **4**, $[\alpha]_{D}^{25}$ 31.8 (*c* 0.26, MeOH); **5**, $[\alpha]_{D}^{25}$ 88.6 (*c* 0.7, MeOH); **6**, $[\alpha]_{D}^{25}$ 42.4 (*c* 0.67, MeOH); **7**, $[\alpha]_{D}^{25}$ 27.3 (*c* 2.2, CHCl₃).

References

- Jiangsu New Medical College, A Dictionary of Traditional Chinese Drugs, pp. 1889–1890, Shanghai People's Press, Shanghai (1977).
- [2] T. Dou. China Pharm., 7, 45 (1998).
- [3] Y. Zhao, J.M. Yue, Z.W. Lin. Phytochemistry, 44, 459 (1997).
- [4] Q.X. Zheng, Q.C. Zhang, H.D. Sun, Y. Zhao. J. Zhejiang Univ. (Med. Sci.), 31, 406 (2002).
- [5] S.L. Li, J.K. Ding. Acta Bot. Yunnan, 15, 303 (1993).
- [6] Y. Zhao, J.M. Yue, J.K. Ding. Chin. Chem. Lett., 7, 1093 (1996).
- [7] Y.C. Xiao, Q.X. Zheng, Q.J. Zhang, Y. Zhao. Fitoterapia, 74, 459 (2003).
- [8] S.L. Li, J.K. Ding. Acta Bot. Yunnan, 16, 313 (1994).
- [9] S.L. Li, J.K. Ding. Acta Bot. Yunnan, 18, 349 (1996).
- [10] A.H. Zhao, J.X. Wei. Acta Chim. Sin., 52, 517 (1994).
- [11] Y. Zhao, J.M. Yue, Y.N. He. J. Nat. Prod., 60, 545 (1997).
- [12] S.L. Li, K. J, B. Ding. Jiang. Phytochemistry, 49, 2035 (1998).
- [13] S.L. Li, J.K. Ding. Acta Bot. Yunnan, 16, 434 (1994).